Top consulting firm hid opioid conflicts of interest from the FDA, says Congressional reportBMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o1024 (Published 22 April 2022) Cite this as: BMJ 2022;377:o1024
- Owen Dyer
McKinsey & Company, the world’s largest management consulting firm, worked for the US Food and Drug Administration (FDA) while failing to disclose that it was also advising opioid makers, a congressional investigation has found.1 McKinsey’s work included advising Purdue Pharma, the company often blamed for triggering the US opioid epidemic, on how to avoid tougher regulations.
“McKinsey staffed at least 22 consultants at both the FDA and opioid manufacturers on related topics, including at the same time,” said Representative Carolyn Maloney, chairwoman of the powerful Committee on Oversight and Reform. “Behind the scenes McKinsey consultants leveraged their federal connections to secure even more private sector business and tried to influence key public health officials on behalf of clients like Purdue Pharma.”
The revelations come from internal documents made available by the consultancy firm as part of a $600m legal settlement agreed last year with the attorneys general of 47 states.2
At least 37 McKinsey …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.